secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-057047
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3
--------------------------------------------------------------------------------

- Cash $32.3M at March 31, 2024; expects runway into Q2 2025.
- Net loss $7.9M ($0.36/sh) vs $7.6M ($0.55/sh) YoY; R&D $4.3M, G&A $3.6M.
- TPST-1120 plans to advance to pivotal Phase 3 in first-line HCC, subject to FDA feedback.
- TPST-1495 planned for Phase 2 in FAP in 2024 under NCI funding; updated data expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/tpst-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer